IrfanFirdausDO

Hematology • Cincinnati, OH

Hematologic Oncology

Physician

Join to view full profile

Dr. Firdaus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Firdaus' full profile

Already have an account?

Office
11140 Montgomery Rd
Cincinnati, OH 45249
Phone+1 513-564-8580

Fax+1 513-564-8584

Education & Training

University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
Advocate Health Care/Advocate Lutheran General HospitalResidency, Internal Medicine, 1996 - 1999
Des Moines University College of Osteopathic MedicineClass of 1995

Certifications & Licensure

OH State License 1999 - 2027
KY State License 2016 - 2026
IN State License 2020 - 2025
IL State License 1996 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
Completed
Phase 2

Publications & Presentations

PubMed

67 citations
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Zishuo Ian Hu, Johanna C. Bendell, Andrea J. Bullock, Noelle K. LoConte, Hassan Hatoum
Cancer Medicine. 2019-09-01
42 citations
A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna C. Bendell, Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace
The Oncologist. 2017-03-01
19 citations
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction exp...
Khaldoun Almhanna, Maria Luisa Limon Miron, David Wright, Antonio Cubillo Gracian, Richard A. Hubner
Investigational New Drugs. 2017-02-11

Press Mentions

New Collaboration at Christ Hospital Is Changing the Way Doctors Diagnose and Treat Cancer PatientsNovember 18th, 2022